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Summary
Expanded polyglutamine (polyQ) proteins in Hunting-
ton’s disease (HD) as well as other polyQ disorders
are known to elicit a variety of intracellular toxicities,
but it remains unclear whether polyQ proteins can
elicit pathological cell-cell interactions which are criti-
cal to disease pathogenesis. To test this possibility,
we have created conditional HD mice expressing a
neuropathogenic form of mutant huntingtin (mhtt-
exon1) in discrete neuronal populations. We show
that mhtt aggregation is a cell-autonomous process.
However, progressive motor deficits and cortical neu-
ropathology are only observed when mhtt expression
is in multiple neuronal types, including cortical inter-
neurons, but not when mhtt expression is restricted
to cortical pyramidal neurons. We further demon-
strate an early deficit in cortical inhibition, suggesting
that pathological interactions between interneurons
and pyramidal neurons may contribute to the cortical
manifestation of HD. Our study provides genetic evi-
dence that pathological cell-cell interactions elicited
by neuropathogenic forms of mhtt can critically con-
tribute to cortical pathogenesis in a HD mouse model.*Correspondence: xwyang@mednet.ucla.eduIntroduction
Huntington’s disease (HD) is an adult-onset, autoso-
mal-dominant neurodegenerative disease that is clini-
cally characterized by a triad of movement disorders
(i.e., chorea and bradykinesia), psychiatric symptoms,
and cognitive deficits. In afflicted patients, symptoms
usually progress relentlessly until death in 15–20 years
after disease onset. HD is one of nine neurodegenera-
tive disorders caused by a CAG repeat expansion en-
coding a polyglutamine (polyQ) repeat in otherwise un-
related proteins (Zoghbi and Orr, 2000). In HD, the
mutated Huntingtin (mhtt) protein is ubiquitously ex-
pressed in both neuronal and nonneuronal tissues
(Sharp et al., 1995; Schilling et al., 1995). The polyQ
repeat, located in the N terminus of huntingtin (htt), is
normally less than 36, but is expanded to more than 37
in HD patients (The Huntington’s Disease Collaborative
Research Group, 1993). In all polyQ disorders, there is
an inverse relationship between the length of polyQ and
the age of disease onset. Currently, there is no effective
treatment or cure for HD or any other polyQ disorder.
All polyQ disorders share a common neuropatholog-
ical feature: despite the widespread expression of mu-
tant polyQ proteins, significant neurodegeneration oc-
curs in distinct subsets of neurons in the brain. In HD,
neuordegeneration is mostly confined to striatal me-
dium spiny neurons and, to a lesser extent, to cortical
pyramidal neurons (Vonsattel and DiFiglia, 1998). These
two types of neurons constitute the vast majority (about
80%–90%) of the total neurons in the respective brain
regions. With longer expansion of the polyQ repeats,
cell death pathology in HD as well as other polyQ disor-
ders becomes increasingly less distinct and more over-
lapping (Zoghbi and Orr, 2000). The cellular and molec-
ular mechanisms underlying the selective neuronal
toxicity in HD as well as in other polyQ disorders remain
largely unknown.
A number of pathogenic mechanisms have been im-
plicated in HD. First, mhtt has been shown to exert
dominant toxicity to cause disease-like phenotypes in
a variety of cellular and animal models. In transgenic
mouse models of HD, overexpression of mhtt resulted
in late-onset behavioral and neuropathological pheno-
types mimicking the disease, but deletion of the htt
gene in mice resulted in an embryonic lethal phenotype
and not HD-like neurodegenerative phenotypes (Duyao
et al., 1995). A variety of toxic gain-of-function mecha-
nisms have been implicated in HD pathogenesis. A
common mechanism shared by HD as well as other
polyQ disorders is the progressive accumulation of pro-
tein aggregates containing the mutant polyQ proteins
in the affected neurons (Davies et al., 1997; DiFiglia et
al., 1997). However, the pathogenic role of the polyQ
protein aggregates remains unresolved (Bates, 2003;
Klement et al., 1998; Arrasate et al., 2004). Other patho-
genic mechanisms implicated in HD include transcrip-
tional dysregulation, mitochondrial deficits, proteoso-
mal dysfunction, abnormal endocytosis, axonal transport
deficits, and synaptic dysfunction (Zoghbi and Orr,
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4342000; Dunah et al., 2002; Li et al., 2000; Steffan et al., A
2004; Panov et al., 2002; Bence et al., 2001; Gunawar- c
dena et al., 2003; Zeron et al., 2002). In addition to the i
gain-of-function pathogenic mechanisms, recent studies c
using cellular models of HD also suggested that loss of t
normal htt function, including regulation of transcription i
and vesicular transport of BDNF, may also contribute i
to HD pathogenesis (Zuccato et al., 2001; Gauthier et i
al., 2004). Together, current evidence suggests that a p
combination of gain-of-function and loss-of-function 2
mechanisms may be involved in pathogenesis of HD m
(Ross, 2004). n
In HD, there is increasing evidence to support the a
idea that proteolysis of mhtt into toxic N-terminal frag- n
ments containing the polyQ repeat is a critical early i
pathogenic event. In the brains of HD patients, the full- a
length mhtt was shown to be proteolytically cleaved q
into small N-terminal fragments (110–600 amino acids) e
by a variety of proteases, including caspases (Martin- A
dale et al., 1998; Wellington et al., 2002), calpains (Kim i
et al., 2001; Gafni et al., 2004), and a yet unidentified
aspartyl endopeptidase (Lunkes et al., 2002). In both R
HD patients and transgenic mice expressing the full-
length mhtt, accumulation of small aggregated mhtt C
N-terminal fragments in the nucleus and cytoplasm was M
evident prior to the onset of motor deficits and neuro- O
degeneration (DiFiglia et al., 1997; Gutekunst et al., t
1999; Hodgson et al., 1999; Wellington et al., 2002; t
Zhou et al., 2003). Furthermore, in cellular models of d
HD, small mhtt N-terminal fragments are clearly more t
toxic to neurons than the full-length mhtt, suggesting o
that small mhtt fragments are likely to be a critical neu- a
ropathogenic entity in HD (Hackam et al., 1998). Finally, s
mhtt N-terminal fragments (including mhtt-exon1) can s
elicit a variety of HD-like phenotypes ranging from ag- r
gregation and cellular toxicity in yeast (Muchowski et
s
al., 2000) and cultured cell models (Hackam et al., 1998;
a
Arrasate et al., 2004) to progressive motor deficits and
i
neuropathology in transgenic Drosophila (Jackson et
ral., 1998) and transgenic mice (Mangiarini et al., 1996;
cSchilling et al., 1999; Yamamoto et al., 2000; Laforet et
cal., 2001). Transgenic mice expressing mhtt N-terminal
tfragments exhibit a variety of HD-like phenotypes in-
icluding progressive motor deficits, striatal and cortical
ratrophy, reactive gliosis, mhtt aggregation, and alter-
cation of gene expression (ibid; Menalled and Chesselet,
f2002; Yu et al., 2003; Luthi-Carter et al., 2000). Together,
Sexisting evidence supports the “toxic fragment hypothe-
msis,” which states that polyQ-containing mhtt N-terminal
mfragments generated by proteolysis of the full-length mhtt
tare the critical pathogenic entity that mediates neuronal
rdysfunction and degeneration in HD (Leavitt et al.,
a1999; Ross, 2002). Therefore, cellular and transgenic
tanimal models expressing neuropathogenic mhtt N-ter-
cminal fragments are widely used to study HD patho-
egenic mechanisms downstream of the proteolysis of
cthe full-length mhtt into the toxic N-terminal fragments.
bDespite significant progress in HD research, many
scritical issues remain to be addressed (Tobin and
cSigner, 2000; Ross, 2002; Ross, 2004). One such issue
tis whether neuronal dysfunction and degeneration in
nHD are solely caused by cell-autonomous toxicities of
tmhtt (cell-autonomy model) or require pathological in-
teractions between cells (cell-cell interaction model)? Ss summarized above, much has been learned about
ell-autonomous toxicities of mhtt. However, very little
s known about the possible role of mhtt in pathological
ell-cell interactions and their relative contribution to
he overall pathogenesis of HD. A few recent studies
n HD mice have suggested that pathological cell-cell
nteractions may be present in vivo. Such interactions
nclude blocking transcription and/or vesicular trans-
ort of BDNF (Zuccato et al., 2001; Gauthier et al.,
004), generating abnormal corticostriatal neurotrans-
ission (Cepeda et al., 2003), and alterations in other
onneuronal cell types, including astrocytes (Lievens et
l., 2001) and microglia (Sapp et al., 2001). Yet, there is
o direct evidence to support that pathological cell-cell
nteractions are critical to HD pathogenesis in vivo in
mouse model. In this study, we asked the following
uestions: Can a neuropathogenic form of mhtt (mhtt-
xon1) elicit pathological cell-cell interactions in vivo?
re such interactions critical to cortical pathogenesis
n HD mice?
esults
reating a Cre/LoxP Conditional Mouse
odel of HD
ur strategy to test the cell-autonomy model versus
he cell-cell interaction model was to develop condi-
ional HD mice that express a toxic mhtt fragment in
iscrete neuronal populations: either in all neurons in
he brain or restricted to cortical pyramidal neurons,
ne of the vulnerable neuronal types in HD. The cell-
utonomy model predicts that restricting mhtt expres-
ion to the cortical pyramidal neurons alone should be
ufficient to cause significant pathology in these neu-
ons. The cell-cell interaction model predicts that re-
tricting mhtt expression to cortical pyramidal neurons
lone will be insufficient to cause significant pathology
n these neurons. Only mhtt expression in multiple neu-
onal types should cause significant pathology in corti-
al pyramidal neurons secondary to pathological cell-
ell interactions with other types of neurons. To test
hese models in vivo, we created conditional HD mice
n which expression of mhtt-exon1 with a 103 glutamine
epeat was completely dependent on Cre-mediated ex-
ision of a transcription termination (STOP) sequence
lanked by two Cre binding sites (LoxP) (Nagy, 2000;
oriano, 1999; Srinivas et al., 2001) (Figure 1A). In this
ouse model (RosaHD), mhtt-exon1 is targeted to the
urine Rosa26 locus, hence its expression is driven by
he endogenous murine Rosa26 promoter, which di-
ects ubiquitous transgene expression (Zambrowicz et
l., 1997). RosaHD mice were crossed with two Cre
ransgenic mice: Nestin-Cre, which activates LoxP re-
ombination in all neurons and glia in the brain (Tronche
t al., 1999), and Emx1-Cre, which activates LoxP re-
ombination in all cortical pyramidal neurons and glia,
ut not in cortical interneurons or striatal neurons (Iwa-
ato et al., 2000; Gorski et al., 2002). Therefore, a criti-
al difference between these two Cre mouse lines in
he cortex is that Nestin-Cre is active in all pyramidal
eurons (about 80% of the cortical neurons) and inhibi-
ory interneurons (about 20% of the cortical neurons;
omogyi et al., 1998); while Emx1-Cre is only active in
Pathological Cell-Cell Interactions in HD Mice
435Figure 1. Generation of the Cre/LoxP Condi-
tional Mouse Model of HD
(A) The schematics of conditional HD mice in
which expression of mhtt-exon1 was com-
pletely dependent on expression of Cre re-
combinase. Mutant htt-exon1 was targeted
to the Rosa26 locus in ES cells. The targeted
locus contains the endogenous Rosa26 pro-
moter, a transcriptional STOP sequence, two
loxP sites (black triangles), mhtt-exon1 with
a polyQ repeat containing 103 glutamine,
and a polyadenylation signal (PA).
(B) Western blot analyses of mhtt-exon1 ex-
pression in the conditional HD mice with the
1C2 antibody. Lane 1, RosaHD/Emx1-Cre
cortex; lane 2, striatum; lane 3, RosaHD/Nes-
tin-Cre cortex; lane 4, striatum.
(C and D) Open field tests for the conditional
HD mice. RosaHD/Nestin-Cre and RosaHD/
Emx1-Cre transgenic mice and their respective wild-type littermates were tested in an open field test at 2, 6, 8, and 10 months of age.
Horizontal locomotor activity of a mouse over a 10 min period was quantified by counting the number of lines crossed by all four limbs. A
Student’s t test with a critical value of p < 0.05 was used for all statistical analyses. Values are mean ± SEM, *p = 0.05; **p = 0.035; ***p = 0.02.cortical pyramidal neurons and not in interneurons. Be-
cause the Rosa26 promoter expresses predominantly
in neurons and expresses very little in glia (Anthony et
al., 2004), RosaHD/Nestin-Cre mice expressed mhtt-
exon1 in all neurons of the brain, and RosaHD/Emx1-
Cre mice expressed mhtt-exon1 only in cortical pyrami-
dal neurons. The cellular distribution of mhtt in these
two mouse models was further confirmed by immuno-
staining of brain sections using a mhtt-specific anti-
body (see below).
To determine mhtt-exon1 expression levels in these
two models, we performed Western blot analyses using
the 1C2 antibody against the expanded polyQ stretch
(Trottier et al., 1995) (Figure 1B). We detected the 42
kDa mhtt-exon1 bands with similar intensities in the
cortices of both models, but significant amounts of
mhtt-exon1 were detected only in the striata of Ro-
saHD/Nestin-Cre mice. These results demonstrate that
RosaHD mice can conditionally express mhtt-exon1 in
a Cre-dependent manner.
Motor Phenotype
We next examined the mice for motor deficits using the
open field test, which quantifies their locomotor activity
(Menalled et al., 2002). Progressive deterioration in lo-
comotor activity has been observed in other mouse
models of HD (Menalled and Chesselet, 2002). RosaHD/
Nestin-Cre mice displayed normal horizontal locomotor
activity at 2 months, but had significantly reduced loco-
motor activity at 6, 8, and 10 months of age (Figure 1C).
No locomotor deficits were observed in RosaHD/Emx1-
Cre mice at any age tested (Figure 1D). Thus, in the
conditional HD mice, progressive locomotor deficits
were present only when mhtt was widely expressed in
the brain, and not when mhtt expression was restricted
to the cortical pyramidal neurons alone.
Cell-Autonomous Nuclear Accumulation
and Aggregation of mhtt
Because the nuclear accumulation and aggregation of
neuropathogenic mhtt N-terminal fragments is a patho-
logical hallmark of HD patients (DiFiglia et al., 1997; Gu-tekunst et al., 1999) and this phenotype has also been
recapitulated in existing HD mice (Davies et al., 1997;
Hodgson et al., 1999; Menalled et al., 2002; Schilling et
al., 1999; Laforet et al., 2001), we immunostained the
conditional HD mouse brains with a rabbit polyclonal
EM48 antibody which preferentially recognizes the ag-
gregated form of mhtt (Gutekunst et al., 1999). In
6-month-old RosaHD-Emx1-Cre brains but not in wild-
type littermate control brains, EM48(+) staining was de-
tected throughout the cortex and striatum, as well as
in several other brain regions, including the cerebellum,
midbrain, and brain stem (Figures 2A–2C and Figure S1
in the Supplemental Data available with this article on-
line). In RosaHD/Emx1-Cre mice, however, EM48(+)
staining was highly restricted to the cortex, with only a
few stained cells in the striatum and cerebellum and
only background staining in other brain regions, includ-
ing midbrain and brainstem (Figures 2D–2F; Figure S1).
These results confirm that the expression of mhtt-
exon1 is throughout the brain in RosaHD/Nestin-Cre
mice and is highly restricted to the cortex in RosaHD/
Emx1-Cre mice.
At the cellular level, the EM48 staining patterns in
the cortex are similar between the two conditional HD
mouse models. In cortical layers II and III, the EM48
staining pattern is predominantly diffuse nuclear stain-
ing plus small nuclear and cytoplasmic aggregates
(Figures 2A and 2D). In the large cortical layer V pyrami-
dal neurons, EM48 predominantly stains small nuclear
and neuropil aggregates (Figures 2B and 2E). In RosaHD/
Nestin-Cre striata, the EM48 staining pattern is pre-
dominantly diffuse nuclear staining with small nuclear
aggregates (Figure 2C). Notably, very few neurons in
RosaHD/Emx1-Cre striata are stained with the EM48
antibody (Figure 2F).
To further ascertain the mhtt expression patterns in
cortical neuronal subtypes in these mice, we performed
double immunofluorescent staining. To determine whether
mhtt accumulation occurs in cortical pyramidal neu-
rons, we double stained the brain sections using rabbit
polyclonal EM48 antibodies and mouse monoclonal an-
tibodies against calmodulin-dependent kinase II (Cam-
Neuron
436Figure 2. Cell-Autonomous Nuclear Accumu-
lation and Aggregation of mhtt in the Corti-
ces and Striata of the Conditional HD Mice
(A–C) EM48 antibody staining patterns in the
RosaHD/Nestin-Cre mice. (A) Cortical layers
II and III; (B) cortical layer V; (C) striatum.
(D–F) EM48 staining patterns in RosaHD/
Emx1-Cre mice. (D) Cortical layers II and III;
(E) cortical layer V, (F) striatum. Scale bars,
10 m.KII), a marker for cortical pyramidal neurons (Benson et e
Eal., 1992). As shown in Figure 3A, in the RosaHD/Nestin-
Cre mouse cortices, the vast majority of cells stained m
swith EM48 are also stained with CamKII antibodies (183
CamKII-positive cells out of 214 EM48-positive cells, or m
e86%); in RosaHD/Emx1-Cre mice, nearly all the cells
stained with EM48 are also stained with CamKII(+) (172 m
sCamKII-positive cells out of 179 EM48-positive cells, or
96%). Therefore, in both conditional HD mouse models, s
ithe vast majority of neurons with nuclear accumulation
of mhtt in the cortex are cortical pyramidal neurons.
To determine the extent of mhtt accumulation in cor- N
Stical interneurons in these mice, we performed double
immunofluorescent staining using the rabbit polyclonal c
tEM48 antibody and a mouse monoclonal antibody
against GABA, the neurotransmitter used by cortical in- g
cterneurons but not by cortical pyramidal neurons. As
shown in Figure 3B, in RosaHD/Nestin-Cre cortices, the w
pmajority of GABA(+) cortical interneurons have diffuse
nuclear EM48 staining (31 EM48-positive cells out of m
m42 GABA-positive cells, or 74%). The intensity of EM48
staining in the GABA(+) interneurons in these mice ap- n
tpears to be slightly lower compared to the adjacent
GABA(−) cortical pyramidal neurons, which constitute c
pthe majority of the EM48(+) cells in the cortex. In
RosaHD/Emx1-Cre cortices, GABA(+) cortical interneu- C
grons only have faint cytoplasmic EM48 staining com-
parable to the background staining pattern in the c
pwild-type mice (Figure 3B), thus, none of the GABA(+)
interneurons in RosHD/Emx1-Cre mice exhibit signifi- m
cant EM48 staining (0 EM48-positive cells out of 75
GABA-positive cells). We conclude that RosaHD/Nes- a
gtin-Cre mice but not RosaHD/Emx1-Cre mice accumu-
late aggregated forms of mhtt in the nucleus of corti- t
acal interneurons.
Since both the brain regional distribution and the cel- a
elular distribution of mhtt in the two conditional HD mod-
els match the expression patterns of the respective Cre w
Rmouse lines, these results validate the accuracy of mhttxpression patterns in both models. Furthermore, since
M48 preferentially detects the aggregated form of
htt (Gutekunst et al., 1999), these results also demon-
trate that nuclear accumulation and aggregation of
htt are cell-autonomous processes. Since both mod-
ls had very little EM48(+) staining in the brains at 2
onths of age (data not shown) but had extensive
taining at 6 months of age, these results are also con-
istent with the progressive nature of mhtt aggregation
n the conditional HD mice.
europathology in the Conditional HD Mice
ince cortical pyramidal neurons in both models have
omparable levels of mhtt expression (both driven by
he endogenous murine Rosa26 promoter) and aggre-
ation, a direct comparison of neuropathology in the
ortices of these two models will allow us to assess
hether cell-cell interactions are critical to cortical
athogenesis in the conditional HD mice. If cell-autono-
ous toxicities of mhtt are the only critical pathogenic
echanism in these mice, then the cortical pyramidal
euron pathology should be comparable between the
wo HD models. If cell-cell interactions are critical to
ortical pathogenesis, then significant cortical neuro-
athology should only be observed in RosaHD/Nestin-
re mice but not in RosaHD/Emx1-Cre mice. To distin-
uish between these two models, we examined the
onditional HD mice for several cortical pathological
henotypes previously reported in existing HD mouse
odels.
We first examined reactive gliosis, a pathological re-
ction of glia secondary to neuronal dysfunction or de-
eneration (Ridet et al., 1997) reported in both HD pa-
ients (Vonsattel and DiFiglia, 1998) and HD mice (Yu et
l., 2003). We stained 6-month-old mouse brains with
nti-GFAP antibodies to label the reactive glia (Ridet
t al., 1997). Surprisingly, the extent of reactive gliosis
as dramatically different between the two models. In
osaHD/Nestin-Cre mice, the density of GFAP(+) cells
Pathological Cell-Cell Interactions in HD Mice
437Figure 3. Patterns of Mutant htt Accumulation in the Cortical Py-
ramidal Neurons and Interneurons in the Conditional HD Mice
(A) Mutant htt accumulation in cortical pyramidal neurons in the
conditional HD mice. In 6-month-old brains of both HD models,
double immunofluorescent staining shows that the majority of cells
with nuclear EM48 staining (green) are also stained with CamKII
antibodies (red), a marker for cortical pyramidal neurons. Colocali-
zation of the two staining patterns is shown as yellow (white ar-
rows). (B) Mutant htt accumulation in the cortical interneurons in
the conditional HD mice. Double immunofluorescent staining was
performed using the EM48 antibody and a murine monoclonal anti-
body against GABA, a neurotransmitter used by the interneurons.
In RosaHD/Nestin-Cre cortices, the majority of GABA(+) cortical in-
terneurons (red) have diffuse nuclear EM48 staining (green). In
RosaHD/Emx1-Cre cortices, GABA(+) cortical interneurons only
have faint cytoplasmic EM48 staining comparable to the back-
ground staining pattern in the wild-type mice. White arrowheads
indicate GABA(+) interneurons in each panel. Scale bars, 20 m.in the cortex was approximately 9-fold greater than in
wild-type littermate controls (p = 0.002, Student’s t test;
Figures 4A, 4C, and 4G) and 6-fold greater in the stria-
tum (p = 0.03, Student’s t test; Figures 4D, 4F, and 4H).
In RosaHD/Emx1-Cre mice, despite mhtt expression
and aggregation in about 80%–90% of the cortical neu-
rons, the density of GFAP (+) cells in the cortex and
striatum was not significantly different from their wild-type littermate controls (Figures 4B, 4E, 4G and 4H).
Since the Rosa26 promoter drives gene expression
mostly in the neurons and very little in the glia (Anthony
et al., 2004), we interpret the robust reactive gliosis ob-
served in the RosaHD/Nestin-Cre mice as a secondary
effect due to neuronal dysfunction, rather than due to
a primary deficit in the glia. This result suggests that
dysfunction of non-pyramidal neurons in the cortex
(primarily cortical interneurons) or sub-cortical neurons
is required to elicit cortical reactive gliosis in the condi-
tional HD mice.
Since cortical pyramidal neurons are vulnerable to
neuronal dysfunction and degeneration in HD (Vonsat-
tel and DiFiglia, 1998) and these neurons express com-
parable levels of mhtt in our two HD mouse models, we
next examined the cellular morphology of these neu-
rons. In an existing HD mouse model, cortical pyrami-
dal neurons were shown to exhibit abnormal wavy api-
cal dendrites called dysmorphic neurites (Laforet et al.,
2001). Using Golgi staining, we examined 6-month-old
transgenic mice and wild-type littermates for this phe-
notype (n = 2 for each genotype; Figures 5A and 5C).
Among the fully impregnated cortical pyramidal neu-
rons, we found that 35 out of 37 neurons in RosaHD/
Nestin-Cre mice exhibited dysmorphic neurites. This
was a significantly higher proportion than in controls (5
out of 40, p < 0.001, χ2 test). We were also able to visu-
alize dysmorphic neurites in RosaHD/Nestin-Cre mice
by biocytin injections into cortical pyramidal neurons
followed by immunostaining (Figure 5D). In RosaHD/
Emx1-Cre mice, only 8 out of 45 cortical pyramidal neu-
rons displayed kinky apical dendrites (Figure 5B), which
was not significantly different from their wild-type litter-
mate controls (4 out of 40 neurons; p > 0.05, χ2 test).
These results demonstrate that restricted expression of
mhtt to cortical pyramidal neurons is insufficient for
pathogenesis of dysmorphic neurites in these neurons,
and expression of mhtt in other neuronal types in the
brain is required.
We subsequently examined the HD mice for neurode-
generation. Existing HD mouse models expressing mhtt
N-terminal fragments exhibit moderate neurodegenera-
tion; these degenerating neurons stain darkly with os-
mium under electron microscopy (EM) and are thus
called dark neurons (Turmaine et al., 2000; Yu et al.,
2003). We employed EM to examine brains of 1-year-
old HD mice for the presence of dark neurons. In the
RosaHD/Nestin-Cre cortices (Figures 5E and 5F) and
striata (Figure 5G) but not in wild-type controls (data
not shown), we detected dark neurons with characteris-
tic ultrastructural features, including enhanced osmium
staining, nuclear and cytoplasmic condensation, irregu-
lar nuclear border, and a lack of clear morphology of
subcellular organelles. The dark neurons in cortical
layer V have the characteristic morphology of pyrami-
dal neurons (Figure 5F). Reactive glia with enhanced
electron density at the nuclear border is often found
adjacent to the dark neurons (Figures 5F and 5G). We
did not observe any dark neurons in the 1-year-old
RosaHD/Emx1-Cre brains. We only observed a few cor-
tical pyramidal neurons with dark lysosome-like cyto-
plasmic vacuoles suggesting early degenerative changes
(Figure 5H; Yu et al., 2003). Striatal neurons from
RosaHD/Emx1-Cre mice displayed normal ultrastruc-
Neuron
438Figure 4. Reactive Gliosis in the Cortex and Striatum of 6-Month-Old RosaHD/Nestin-Cre Mice but Not RosaHD/Emx1-Cre Mice
Six-month-old HD mouse brains were stained with anti-GFAP antibodies to label the reactive glia. Robust reactive gliosis, as indicated by
increase in GFAP staining, is detected only in the cortices and striata of the RosaHD/Nestin-Cre mice and not in the RosaHD/Emx1-Cre mice.
(A) RosaHD/Nestin-Cre cortex; (B) RosaHD/Emx1-Cre cortex; (C) wild-type cortex; (D) RosaHD/Nestin-Cre striatum; (E) RosaHD/Emx1-Cre
striatum; (F) wild-type striatum. (G and H) Quantitation of GFAP(+) reative glia density in the HD mice is shown for the cortex (G) and striatum
(H). Student’s t test is used for statistics; values are mean ± SEM, *p = 0.002, **p = 0.03. Scale bar, 100 m.tural features (Figure 5I). These results demonstrate s
that pathogenesis of dark neuron degeneration in the t
cortical pyramidal neurons also requires mhtt expres- H
sion in other types of neurons in the brain, and cell- o
autonomous toxicities of mhtt can only elicit very mild m
degenerative changes (i.e., degenerating vacuoles) in s
cortical pyramidal neurons. w
In summary, our neuropathological studies show that o
restricting mhtt expression to cortical pyramidal neu- W
rons produced very limited pathology in these neurons, t
hence our results do not support the cell-autonomy a
model. Furthermore, since mhtt expression in multiple s
neuronal types in RosaHD/Nestin-Cre mice reproduced w
several characteristic cortical phenotypes seen in other p
HD mice and HD patients, these results support the I
cell-cell interaction model for cortical pathogenesis in p
the conditional HD mice. t
p
pPresynaptic Changes in GABAergic
1Neurotransmission Suggesting Cortical Interneuron
GDysfunction in the Conditional HD Mice
cOur findings suggest that neuronal dysfunction in corti-
ical interneurons or subcortical neurons are critical to
pthe pathogenesis of the cortical pyramidal neurons. To
Cgain further insights into which neuronal types may be
edysfunctional early in the RosaHD/Nestin-Cre mice, we
employed whole-cell patch-clamp recordings in brain alices to examine both excitatory and inhibitory synap-
ic inputs to cortical pyramidal neurons in 6-month-old
D mice. This is the earliest time point at which we
bserved motor deficits and neuropathology in these
ice. We first examined excitatory input by recording
pontaneous excitatory postsynaptic currents (sEPSCs),
hich result from spontaneous glutamate release by
ther cortical and thalamocortical excitatory neurons.
e observed no significant differences in the proper-
ies of sEPSCs between the RosaHD/Nestin-Cre mice
nd controls (Figure 6A; Table 1). We then recorded
pontaneous inhibitory postsynaptic currents (sIPSCs),
hich originate from the spontaneous, GABAergic in-
ut of cortical interneurons onto the pyramidal neurons.
n RosaHD/Nestin-Cre mice, we found that the average
eak amplitude of sIPSCs was similar to controls, but
hat sIPSC frequency was significantly reduced com-
ared to the controls (15.1 ± 1.9 versus 20.9 ±1.4 Hz,
= 0.017, Student’s t test) (Figures 6B and 6C; Table
). Since sIPSC frequency is a function of presynaptic
ABA release secondary to action potential firing by
ortical interneurons, this result suggests that cortical
nterneurons become dysfunctional early in the disease
rocess in RosaHD/Nestin-Cre mice. In RosaHD/Emx1-
re mice, we did not observe any significant differ-
nces in the properties of sIPSCs, including frequency
nd amplitude, from those recorded in wild-type control
Pathological Cell-Cell Interactions in HD Mice
439Figure 5. Pathogenesis of Dysmorphic Neu-
rites and Dark Neuron Degeneration in the
Conditional HD Mice
Golgi staining was used to reveal the mor-
phology of the apical dendrites in the corti-
cal pyramidal neurons. (A) In RosaHD/Nes-
tin-Cre mice, numerous cortical pyramidal
neurons exhibit dysmorphic neurites with
torturous and wavy apical dendrites. (B) In
RosaHD/Emx1-Cre mice, the majority of the
pyramidal neurons exhibit normal apical
dendrite morphology. (C) In wild-type mice,
cortical pyramidal neurons also exhibit nor-
mal apical dendrite morphology. (D) Biocytin
injection followed by immunostaining re-
vealed dysmophic neurites in cortical py-
ramidal neurons of 6-month-old RosaHD/
Nestin-Cre transgenic brains (left panel) but
not in those of the wild-type littermate con-
trols (right panel). (E–I) Electron microscopy
(EM) studies of brains from 1-year-old condi-
tional HD mice and wild-type control mice.
(E–G) Degenerating dark neurons in the
RosaHD/Nestin-Cre brains. (E) Two dark
neurons in cortical layer II and III; (F) one
dark pyramidal neuron in cortical layer V; an
adjacent reactive glia with enhanced nuclear
border staining (asterisk); (G) two striatal
dark neurons with an adjacent reactive glia
(asterisk). (H and I) In RosaHD/Emx1-Cre
mice, we did not observe any dark neurons
at 1 year of age. We only observed a few cortical pyramidal neurons with dark lysosome-like cytoplasmic vacuoles (white arrows) suggesting
early degenerative changes (H), and striatal neurons from RosaHD/Emx1-Cre mice displayed normal ultrastructural features (I).mouse models to test whether a neuropathogenic form fore, we conclude that pathological cell-cell interac-
Table 1. Properties of sIPSCs and sEPSCs in Cortical Pyramidal Neurons of RosaHD/Nestin-Cre Mice and RosaHD/Emx1-Cre Mice
Amplitude (pA) Frequency (Hz) RT10%–90% (s) τw (ms) Number of Cells
RN, sIPSCs
Control −34.6 ± 3.3 20.9 ± 1.4 428 ± 21 4.12 ± 0.2 15
RN −33.7 ± 2.8 15.1 ± 1.9* 453 ± 22 4.81 ± 0.4 13
RE, sIPSCs
Control −35.1 ± 1.8 20.0 ± 2.5 400 ± 21 4.24 ± 0.3 9
RE −30.3 ± 2.2 17.4 ± 2.3 409 ± 15 4.27 ± 0.3 8
RN, sEPSCs
Control −12.5 ± 1.2 10.1 ± 1.2 563 ± 29 2.56 ± 0.2 8
RN −12.8 ± 1.1 10.2 ± 1.2 565 ± 62 2.51 ± 0.3 8
Values are mean ± SE. *p = 0.017. RN, RosaHD/Nestin-Cre; RE, RosaHD/Emx1-Cre.mice (Figures 6B and 6C; Table 1). Since the presence
of sIPSC abnormalities is correlated with the expres-
sion of mhtt in cortical interneurons in these mice (Fig-
ure 3B), this result suggests that mhtt expression in
cortical interneurons may lead to reduced GABAergic
input to the cortical pyramidal neurons in the RosaHD/
Nestin-Cre mice. Together, our electrophysiological
studies show that the reduction of GABAergic inhibitory
input onto cortical pyramidal cells is an early pheno-
type in RosaHD/Nestin-Cre mice but not in RosaHD/
Emx1-Cre mice (Figure 6D). Thus, pathological interac-
tions between cortical interneurons and pyramidal neu-
rons may be critical for cortical pathogenesis in HD.
Discussion
In this study, we have created Cre/LoxP conditionalof mhtt (mhtt-exon1) can elicit significant pathological
cell-cell interactions that critically contribute to cortical
pathogenesis in vivo. We found that restricting mhtt ex-
pression to cortical pyramidal neurons is sufficient to
produce mhtt nuclear accumulation and aggregation in
these neurons, but is insufficient to produce other corti-
cal neuropathology or motor deficits. However, expres-
sion of mhtt in all the neurons in the brain elicits both
progressive motor deficits and certain characteristics
of HD cortical pathology including mhtt nuclear accu-
mulation and aggregation, reactive gliosis, dysmorphic
neurites, and dark neuron degeneration (Vonsattel and
DiFiglia, 1998; Menalled and Chesselet, 2002; Yu et al.,
2003). These results provide genetic evidence that ex-
pression of neuropathogenic forms of mhtt fragments
outside the cortical pyramidal neurons can critically
contribute to the pathogenesis of these neurons; there-
Neuron
440Figure 6. Presynaptic Changes in GABAergic Neurotransmission in 6-Month-Old RosaHD/Nestin-Cre Mouse Cortex, but Not in RosaHD/Emx-
Cre Mouse Cortex, while Glutamatergic Transmission Remains Unaltered
All recordings were performed in layer II/III pyramidal neurons in the motor cortex. (A) AMPA receptor-mediated spontaneous EPSCs (sEPSCs)
recorded in wild-type (wt; n = 8 cells) and RosaHD/Nestin-Cre (RN; n = 8 cells) transgenic mice show similar frequencies, rise times, amplitudes
and decay time constants. Sample traces depict raw EPSCs, with superimposed average sEPSCs traces from >100 events in wild-type
controls (black trace) and RosaHD/Nestin-Cre mice (gray trace). (B) GABAA receptor-mediated spontaneous IPSCs (sIPSCs) in the RosaHD/
Emx1-Cre (RE; n = 8 cells) mice are comparable to those in wild-type (n = 9 cells) mice, but the frequency of IPSCs in the RosaHD/Nestin-
Cre (RN; n = 13 cells) mice is significantly reduced compared to those in wild-type (n = 15 cells) mice. Raw traces and superimposed events
are shown. (C) The comparison of sIPSC frequencies is expressed in the left panel. Data are presented as mean ± SEM. Error bars denote
SEM, and asterisks indicate significance (p < 0.01, two-tailed t test). Scatter plots (right panel) indicate the mean frequencies recorded in
each cell. (D) Schematic models to summarize the neuropathological and electrophysiological analyses of the two conditional HD models.
Our results suggest that early cortical interneuron dysfunction in RosaHD/Nestin-Cre mice leads to reduced cortical inhibition which in turn
contributes to overall cortical pathogenesis. Mutant htt expression (dotted black circle); dark degenerating neurons (spiked gray circle);
degenerating vacuoles (small black stars); reduced GABAergic neurotransmission (dotted lines); reactive glia (large black star).tions can significantly contribute to neuronal toxicity in r
nvivo in a mouse model of HD.
Another significant finding of this study is the demon- s
pstration of cortical interneuron dysfunction, primarily a
reduction of GABAergic neurotransmission, in the con- 2
aditional HD mice. Several observations support the in-
terpretation that cortical interneuron dysfunction is im- r
cportant for HD pathogenesis. First, our results suggest
that expression of mhtt outside cortical pyramidal neu- (
2rons, including cortical interneurons or subcortical neu-
rons, is critical for cortical pathogenesis. Second, the e
ppresence of interneuron dysfunction is correlated with
the expression and accumulation of aggregated forms a
aof mhtt in the cortical interneurons in the conditional
HD mice. Third, interneuron dysfunction appears very w
iearly in the disease process, at 6 months of age, which
is the earliest time point we could detect locomotor c
ideficits and neuropathology in these mice. These re-
sults strongly argue that the reduction of GABAergic d
gneurotransmission may be a critical early pathogenic
event in the conditional HD mice. Our observation of
ccortical interneuron dysfunction is also consistent with
alterations of interneuron gene expression in the brains p
aof HD patients (Ferrer et al., 1994) and with previouseports on mhtt aggregation in subsets of cortical inter-
eurons and on alterations of interneuron gene expres-
ion in the R6/2 mouse model of HD, which also ex-
resses mhtt-exon1 (Kosinski et al., 1999; Meade et al.,
002; Gourfinkel-An et al., 2003). Cortical interneurons
re critical for regulating the excitability of cortical py-
amidal neurons (Mody and Pearce, 2004). Enhanced
ortical excitability has been observed in HD patients
i.e., seizures in juvenile HD patients; Nance and Myers,
001) and HD mice (Cepeda et al., 2003). In turn, such
nhanced cortical excitability has been postulated to
romote excitotoxicity in striatal medium spiny neurons
nd contribute to their degeneration in HD (Grunewald
nd Beal, 1999). Taking everything into account, we
ould like to propose a pathogenic model for HD that
nvolves dysfunctional cortical and striatal neuronal cir-
uitry. That is, the early cortical interneuron dysfunction
n HD leads to enhanced excitability of cortical pyrami-
al neurons, which in turn contributes to neuropatho-
enesis in the cortex and striatum.
Our study has clearly demonstrated that pathological
ell-cell interactions are critically important for cortical
athogenesis in a conditional mouse model expressing
neuropathogenic form of mhtt (mhtt-exon1). Our
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441study, however, did not directly address the relative
contribution of pathological cell-cell interactions in HD
pathogenesis elicited by the full-length mhtt. Since full-
length mhtt was shown to be cleaved into toxic mhtt
N-terminal fragments similar to the size of mhtt-exon1
(Lunkes et al., 2002) and accumulation of such mhtt
fragments in aggregates precedes the onset of motor
deficits and neurodegeneration in HD patients and HD
mice (DiFiglia et al., 1997; Gutekunst et al., 1999; Wel-
lington et al., 2002; Zhou et al., 2003), we therefore
would like to suggest that pathological cell-cell interac-
tions also contribute to cortical pathogenesis elicited
by the full-length mhtt, particularly after accumulation
of small mhtt N-terminal fragments in the cortical neu-
rons. Future genetic studies using conditional mouse
models expressing full-length mhtt are clearly needed
to directly address this issue.
Our study demonstrates that expression of mhtt in
cortical pyramidal neurons is insufficient to cause sig-
nificant cortical disease in our mouse model. Neverthe-
less, we cannot rule out the possibility that mhtt ex-
pression in cortical pyramidal neurons is necessary for
disease pathogenesis. There are two possible scenar-
ios. One is that expression of mhtt in the pyramidal neu-
rons is necessary but not sufficient for cortical patho-
genesis. Another scenario is that expression of mhtt
outside the cortical pyramidal neurons, such as cortical
interneurons or subcortical neurons, is both necessary
and sufficient to cause full-scale cortical disease, even
in the absence of mhtt expression in the cortical pyra-
midal neurons. Since restricted expression of mhtt to
the cortical pyramidal neurons can elicit mild neurode-
generative changes in these neurons, we believe that
the first scenario is likely to be true. Expression of mhtt
restricted to the vulnerable neurons alone can elicit a
very mild and slowly progressing cell-autonomous dis-
ease process, but a combination of this cell-autono-
mous process with pathological cell-cell interactions
will cause the full-scale disease affecting the vulnerable
neurons. Further studies using mouse models that se-
lectively turn on mhtt expression in the cortical inter-
neurons or striatal medium spiny neurons will help to
address these questions.
Our study also provides insights into the role of mhtt
aggregation in HD pathogenesis. The conditional HD
mice revealed that progressive mhtt nuclear accumula-
tion and aggregation is a cell-autonomous process.
However, the presence of mhtt aggregates in cortical
pyramidal neurons alone can only elicit very mild neuro-
degenerative changes (i.e., degenerating vacuoles), but
cannot elicit full-scale neuropathology in these neurons
(including dysmorphic neurites and dark neuron degen-
eration). These results demonstrate that the aggregates
themselves cannot be the only pathogenic factor in
cortical pyramidal neurons. This result is consistent
with studies on SCA1 mouse models demonstrating
that large nuclear inclusions are not pathogenic and
may even be neuroprotective (Klement et al., 1998).
However, we cannot rule out the possibility that mhtt
aggregates may be necessary for cortical pathogene-
sis, since the appearance of these aggregates in the
RosaHD/Nestin-Cre mice is concurrent with the onset
of motor deficits, interneuron dysfunction, and cortical
pathology.Finally, our study has important implications for un-
derstanding the pathogenesis of other neurodegenera-
tive disorders, including other polyQ disorders, familial
Alzheimer’s disease, and familial Parkinson’s disease.
All of these disorders are characterized by selective
neurodegeneration caused by widely expressed dis-
ease proteins, but the molecular and cellular mecha-
nisms underlying selective neruodegeneration in these
disorders are poorly understood. A recent study of
amyotrophic lateral sclerosis (ALS), a neurodegenera-
tive disorder affecting the motor neurons, demon-
strated that pathological cell-cell interactions elicited
by mutant superoxide dismutase 1 is critical to selec-
tive motor neuron degeneration seen in ALS chimeric
mice (Clement et al., 2003). Together, our study as well
as the ALS study suggests that pathological cell-cell
interactions may be a surprisingly common pathogenic
mechanism that warrants further studies in all neurode-
generative disorders.
Experimental Procedures
Generation and Breeding of the Conditional HD Mice
Human mhtt-exon1 with 103 mixed CAA-CAG repeat encoding a
glutamine repeat (Kazantsev et al., 1999) was targeted to the
Rosa26 locus in 129Sv ES cells as described (Srinivas et al., 2001).
Five correctly targeted ES cell clones were identified by Southern
blot analyses (data not shown), and these ES cell clones were
microinjected into C57BL/6J mouse blastocysts to obtain chimera
mice. Two chimera mice produced germline transmission of the
correctly targeted allele.
Rosa HD mice were maintained as 129 and C57BL/6J hybrids.
Nestin-Cre mice (Tronche et al., 1999) were maintained on a C57BL/
6J background, and Emx1-Cre mice (Iwasato et al., 2000) were
generated in the 129Sv background and backcrossed onto the
C57BL/6J background. The F1 and F2 mice from crosses between
RosaHD mice and the Cre mice (all in a mixed 129Sv and C57BL6J
hybrid background) were used in this study. Wild-type littemates
were used as controls. RosaHD, Nestin-Cre, and Emx-Cre alleles
were genotyped using the established PCR protocols (Srinivas et
al., 2001; Tronche et al., 1999; Iwasato et al., 2000). Mice were
maintained and bred under standard conditions, consistent with
National Institutes of Health guidelines and approved by the Institu-
tional Animal Care and Use Committees.
Western Blot Analyses
Cortical and striatal tissues from 6-month-old mouse brains were
dissected out separately and resuspended in lysis buffer (0.1 M Tris
[pH 7.4], 1 mM EDTA, and 50 mM NaCl) with a protease inhibitor
cocktail (Roche, Palo Alto, CA), homogenized for 30 s, then centri-
fuged for 10 min at 12,000 × g at 4°C. The supernatant was col-
lected and stored at −80°C. Protein samples (100 g) were loaded
onto a 7.5% mini-gel and separated by electrophoresis. After
transfer to PVDF membrane (Perkin Elmer), mhtt was detected with
the mouse monoclonal 1C2 antibody (1:2000 dilution; Chemicon)
and enhanced chemiluminesce (Amersham). The membrane was
striped and reprobed with a β-actin antibody (1:2000 dilution;
Sigma) to confirm the equal loading of samples.
Open Field Test
Naive animals were tested in an open field test at 2, 6, 8, and 10
months of age. For RosaHD/Nestin-Cre mice, the following number
of transgenic (Tg) and wild-type (wt) mice were used: 2 months, 16
Tg and 17 wt; 6 months, 20 Tg and 28 wt; 8 months, 9 Tg and 14
wt; 10 months, 14 Tg and 18 wt. For the RosaHD/Emx1-Cre mice,
the following numbers of mice were used: 2 months, 11 Tg and 12
wt; 6 months, 16 Tg and 14 wt; 8 months, 14 Tg and 19 wt; and 10
months, 9 Tg and 13 wt. They were tested and videotaped over a
10 min period according to an established protocol (Menalled et
al., 2002). All tests were performed at the same time of day. The
Neuron
442open field consisted of a clear Plexiglass box (15 × 30 × 45cm) in O
twhich the floor was divided into two rows of three squares each.
Each mouse was initially placed in the middle square of the back 2
Wrow. Horizontal locomotive activity of a mouse was defined as the
number of lines crossed by all four limbs over the testing period. e
IVideotapes were reviewed by two examiners who were blind to the
genotypes of the mice, and the average crossing number between t
mthe two examiners was used for each mouse. A Student’s t test
with a critical value of p < 0.05 was used for all statistical analyses. t
5
mImmunohistochemical and Double-Immunofluorescent Staining
wof Mouse Brain Sections with the EM48 Antibodies
aMutant htt was detected by using an established immunohisto-
mchemical staining protocol with the rabbit polyclonal EM48 anti-
tbody (Menalled et al., 2002). Sections were imaged using a Zeiss
Axioskop 2 microscope.
For double immunofluorescent studies, 35 m brain sections
Swere prepared as above. Floating sections were blocked 30 min
Twith 2% normal goat serum and 3% bovine serum albumin (BSA).
wAfter incubation with rabbit polyclonal EM48 antibodies (1:300 dilu-
tion) at room temperature for 18 hr, sections were stained overnight
at 4°C with a second primary antibody, either mouse monoclonal
anti-CaMKII antibody (1:200 dilution, Chemicon) or mouse mono- A
clonal anti-GABA antibody (1:1000 dilution, Sigma). Alexa Fluor
488-conjugated goat anti-rabbit IgG antibodies and Alexa Fluor X
568-conjugated goat anti-mouse IgG antibodies (Molecular Probes) e
were then applied to the sections at 1:200 dilution and incubated g
2 hr in the dark at room temperature. Stained sections were g
washed three times for 10 min each in 0.1 M Tris buffer (pH 7.6), W
mounted in Vectashield (Vector), and images were taken using a s
Leica TCS-SP confocal microscope. R
m
oImmunohistochemistry Detection and Quantitation
Gof Reactive Gliosis
SWe used established protocols for GFAP staining (Yu et al., 2003).
cTo quantify gliosis, we used three 6-month-old transgenic mice and
ithree respective wild-type littermates. Mice were transcardially
tperfused, and serial 40 m coronal sections were prepared. The
first section was chosen at approximately Bregma 0 mm (Paxinos
and Franklin, 2001); this section and three successive sections 240
R
m apart (every sixth section) were stained with anti-GFAP anti-
R
body. To quantify the severity of reactive gliosis, we counted the
A
number of GFAP(+) cells on each section in a fixed rectangular area
P
(138 m × 110 m) under 20× objective on a Zeiss Axioskop 2
microscope. Six nonoverlapping images from each cortical brain
Rsection and four images from each striatal brain section were ob-
tained for the quantitation. We calculated the average number of
AGFAP(+) astrocytes per unit area (mm2) per mouse for both cortex
sand striatum for each genotype. The Student’s t test was used for
sstatistical analysis.
A
bGolgi Staining
hModified Golgi-Cox impregnation of neurons was performed using
BFD Rapid Golgi Stain Kit (FD NeuroTechnologies). In brief, 6-month-
told nonperfused mouse brains were immersed in impregnation so-
lution for 2 weeks, transferred to Solution C for 2 days, and cut into B
100 m sections with cryostat. The sections were mounted on 3% t
gelatin-coated slides, air-dried for 2 weeks, then stained with Solu- 2
tion D and E followed by a serial alcohol dehydration prior to
B
mounting with Permount.
C
y
Electron Microscopy r
We used an established protocol for EM study (Yu et al., 2003). Two
C1-year-old RosaHD/Nestin-Cre and RosaHD/Emx1-Cre transgenic
gmice and two respective wild-type littermates were used for EM
Nstudy.
p
cElectrophysiological Recordings
CBrain slices were prepared by standard techniques as previously
Sdescribed (Dalby and Mody, 2003). The ACSF contained 126 mM
eNaCl, 2.5 mM KCl, 2 mM CaCl2, 2 mM MgCl2, 1.25 mM NaH2PO4,
m26 mM NaHCO3, and 10 mM D-glucose (pH 7.3). The slices were
perfused continuously with 32°C–34°C ACSF saturated with 95% D2 and 5% CO2 at 3 ml/min containing either 3 mM kynurenic acid
o block ionotropic glutamate receptors or 50 M picrotoxin and
5 M D-APV to block GABAA and NMDA receptors, respectively.
hole-cell recordings were made in visually identified cortical lay-
rs 3-5 pyramidal neurons with an Axopatch 200 amplifier (Axon
nstruments). The intracellular solutions of sIPSCs recordings con-
ained 125 mM CsCl, 5 mM NaCl, 2 mM MgCl2, 10 mM HEPES, 0.1
M EGTA, 2 mM Na2ATP, 0.5 mM Na-GTP, and 5 mM QX-314, while
he pipette solution of sEPSCs was as follows: 130 mM CsMeSO4,
mM NaCl, 10 mM HEPES, 0.2 mM EGTA, 2 mM MgATP, and 0.2
M Na-GTP (pH 7.25; 280–290 mOsm). Voltage-clamp recordings
ere made at Vh = −70 mV. The sIPSCs and sEPSCs were detected
nd analyzed as described previously (Dalby and Mody, 2003). The
eans were considered to be significantly different if p < 0.05 (t
est).
upplemental Data
he Supplemental Data for this article can be found online at http://
ww.neuron.org/cgi/content/full/46/3/433/DC1/.
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